Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K
Department of Neurosurgery, Sapporo Medical College.
Neurol Med Chir (Tokyo). 1993 Jul;33(7):448-57. doi: 10.2176/nmc.33.448.
Nine patients with malignant brain tumors were treated with intratumoral infusion of lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). LAK cells were generated from macrophage-depleted peripheral blood lymphocytes by culturing with IL-2 for 4 days. The resulting LAK cells showed strong cytotoxic activity against tumor target cells. Three patients received sufficient LAK cells (> or = 5.76 x 10(8)) to show partial tumor response by computed tomography and clinical signs. No severe neurological side effects occurred in any patient. Intratumoral administration of LAK cells and IL-2 can be effective in patients with malignant brain tumors.
9例恶性脑肿瘤患者接受了肿瘤内注射淋巴因子激活的杀伤细胞（LAK细胞）和白细胞介素-2（IL-2）治疗。LAK细胞由去除巨噬细胞的外周血淋巴细胞与IL-2培养4天产生。所产生的LAK细胞对肿瘤靶细胞表现出强烈的细胞毒活性。3例患者接受了足够数量的LAK细胞（≥5.76×10⁸），通过计算机断层扫描和临床体征显示肿瘤有部分缓解。所有患者均未出现严重的神经副作用。肿瘤内注射LAK细胞和IL-2对恶性脑肿瘤患者可能有效。
